GRPH - Graphite Bio, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Graphite Bio, Inc.

201 Haskins Way
Suite 210
South San Francisco, CA 94080
United States
(650) 484-0886

Full-time employees120

Key executives

NameTitlePayExercisedYear born
Dr. Joshua Lehrer-Graiwer FACC, M.D.Pres, CEO & Director785.25kN/A1975
Dr. Matthew Porteus M.D., Ph.D.Academic Founder & Director110kN/A1966
Ms. Alethia Rene YoungChief Financial Officer774.12kN/A1979
Dr. Maria Grazia Roncarolo M.D., Ph.D.Academic Founder & Chair of Scientific Advisory BoardN/AN/A1954
Dr. Daniel Dever Ph.D.Co-Founder & Head of Discovery ResearchN/AN/AN/A
Dr. Christine Garrett P.M.P., Ph.D.Chief of Staff & Sr. VP of OperationsN/AN/A1971
Mr. Jerry CaciaChief Technical OfficerN/AN/A1967
Stephanie YaoVP of Communications & Investor RelationsN/AN/AN/A
Ms. Julia TranChief People OfficerN/AN/A1977
Mr. Darren Hart B.S.N., J.D.Sr. VP of Devel.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate governance

Graphite Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.